In this review:
Adjuvant ipilimumab vs. interferon-α for resected high-risk melanoma
REGN2810 for unresectable locally advanced or metastatic cutaneous SCC
Long-term pembrolizumab outcomes of ipilimumab-naïve advanced melanoma
OS update for dabrafenib + trametinib for BRAF V600-mutated melanoma
Dabrafenib + trametinib for BRAF V600-mutated melanoma brain metastases
Nivolumab + ipilimumab for melanoma brain metastases
Adding ipilimumab to nivolumab for melanoma brain metastases
Ipilimumab ± talimogene laherparepvec in unresected stage IIIB–IV melanoma
Sorafenib for chemonaïve metastatic uveal melanoma
Anti-LAG-3 plus nivolumab in anti-PD-1/PD-L1-treated melanoma
Please login below to download this issue (PDF)